Regeneron Pharmaceuticals, Inc. (REGN)
USD 581.68
(-4.74%)
USD 581.68
(-4.74%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 33.08 Billion USD | 13.23% |
| 2022 | 29.21 Billion USD | 14.86% |
| 2021 | 25.43 Billion USD | 48.19% |
| 2020 | 17.16 Billion USD | 15.93% |
| 2019 | 14.8 Billion USD | 26.17% |
| 2018 | 11.73 Billion USD | 33.89% |
| 2017 | 8.76 Billion USD | 25.68% |
| 2016 | 6.97 Billion USD | 24.32% |
| 2015 | 5.6 Billion USD | 44.87% |
| 2014 | 3.87 Billion USD | 31.2% |
| 2013 | 2.95 Billion USD | 41.84% |
| 2012 | 2.08 Billion USD | 57.19% |
| 2011 | 1.32 Billion USD | 21.49% |
| 2010 | 1.08 Billion USD | 46.98% |
| 2009 | 741.2 Million USD | 10.62% |
| 2008 | 670.03 Million USD | -28.43% |
| 2007 | 936.25 Million USD | 60.02% |
| 2006 | 585.09 Million USD | 38.16% |
| 2005 | 423.5 Million USD | -10.49% |
| 2004 | 473.1 Million USD | -1.34% |
| 2003 | 479.55 Million USD | 22.47% |
| 2002 | 391.57 Million USD | -20.96% |
| 2001 | 495.39 Million USD | 137.86% |
| 2000 | 208.27 Million USD | 52.02% |
| 1999 | 137 Million USD | -12.68% |
| 1998 | 156.9 Million USD | -6.83% |
| 1997 | 168.4 Million USD | 22.38% |
| 1996 | 137.6 Million USD | 46.7% |
| 1995 | 93.8 Million USD | -0.42% |
| 1994 | 94.2 Million USD | -19.9% |
| 1993 | 117.6 Million USD | 20.12% |
| 1992 | 97.9 Million USD | -14.12% |
| 1991 | 114 Million USD | 348.82% |
| 1990 | 25.4 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 36.08 Billion USD | 5.0% |
| 2024 Q1 | 34.36 Billion USD | 3.9% |
| 2024 Q3 | 37.44 Billion USD | 3.76% |
| 2023 Q1 | 30.05 Billion USD | 2.89% |
| 2023 Q4 | 33.08 Billion USD | 2.85% |
| 2023 FY | 33.08 Billion USD | 13.23% |
| 2023 Q2 | 30.65 Billion USD | 1.99% |
| 2023 Q3 | 32.16 Billion USD | 4.91% |
| 2022 Q2 | 27.2 Billion USD | 3.25% |
| 2022 Q3 | 27.67 Billion USD | 1.73% |
| 2022 FY | 29.21 Billion USD | 14.86% |
| 2022 Q1 | 26.34 Billion USD | 3.59% |
| 2022 Q4 | 29.21 Billion USD | 5.55% |
| 2021 FY | 25.43 Billion USD | 48.19% |
| 2021 Q2 | 21.48 Billion USD | 20.9% |
| 2021 Q1 | 17.77 Billion USD | 3.55% |
| 2021 Q3 | 23.67 Billion USD | 10.17% |
| 2021 Q4 | 25.43 Billion USD | 7.45% |
| 2020 Q2 | 14.42 Billion USD | -8.43% |
| 2020 FY | 17.16 Billion USD | 15.93% |
| 2020 Q1 | 15.75 Billion USD | 6.43% |
| 2020 Q4 | 17.16 Billion USD | 6.71% |
| 2020 Q3 | 16.08 Billion USD | 11.47% |
| 2019 FY | 14.8 Billion USD | 26.17% |
| 2019 Q1 | 12.85 Billion USD | 9.55% |
| 2019 Q2 | 13.17 Billion USD | 2.48% |
| 2019 Q4 | 14.8 Billion USD | 6.21% |
| 2019 Q3 | 13.93 Billion USD | 5.81% |
| 2018 Q4 | 11.73 Billion USD | 8.6% |
| 2018 FY | 11.73 Billion USD | 33.89% |
| 2018 Q3 | 10.8 Billion USD | 8.58% |
| 2018 Q2 | 9.95 Billion USD | 6.18% |
| 2018 Q1 | 9.37 Billion USD | 6.94% |
| 2017 FY | 8.76 Billion USD | 25.68% |
| 2017 Q4 | 8.76 Billion USD | 0.72% |
| 2017 Q1 | 7.81 Billion USD | 12.1% |
| 2017 Q2 | 8.1 Billion USD | 3.7% |
| 2017 Q3 | 8.7 Billion USD | 7.34% |
| 2016 Q3 | 6.82 Billion USD | 10.04% |
| 2016 Q4 | 6.97 Billion USD | 2.13% |
| 2016 Q2 | 6.2 Billion USD | 5.09% |
| 2016 Q1 | 5.9 Billion USD | 5.27% |
| 2016 FY | 6.97 Billion USD | 24.32% |
| 2015 Q4 | 5.6 Billion USD | 8.22% |
| 2015 Q3 | 5.18 Billion USD | 14.49% |
| 2015 Q1 | 4.19 Billion USD | 8.44% |
| 2015 FY | 5.6 Billion USD | 44.87% |
| 2015 Q2 | 4.52 Billion USD | 7.82% |
| 2014 FY | 3.87 Billion USD | 31.2% |
| 2014 Q1 | 3.26 Billion USD | 10.48% |
| 2014 Q2 | 3.45 Billion USD | 6.0% |
| 2014 Q3 | 3.73 Billion USD | 8.2% |
| 2014 Q4 | 3.87 Billion USD | 3.54% |
| 2013 Q4 | 2.95 Billion USD | 11.76% |
| 2013 FY | 2.95 Billion USD | 41.84% |
| 2013 Q1 | 2.27 Billion USD | 9.4% |
| 2013 Q2 | 2.37 Billion USD | 4.49% |
| 2013 Q3 | 2.64 Billion USD | 11.02% |
| 2012 Q1 | 1.35 Billion USD | 2.01% |
| 2012 Q2 | 1.45 Billion USD | 7.95% |
| 2012 Q3 | 1.66 Billion USD | 13.94% |
| 2012 FY | 2.08 Billion USD | 57.19% |
| 2012 Q4 | 2.08 Billion USD | 25.28% |
| 2011 Q2 | 1.04 Billion USD | -2.55% |
| 2011 FY | 1.32 Billion USD | 21.49% |
| 2011 Q4 | 1.32 Billion USD | 34.64% |
| 2011 Q3 | 983.03 Million USD | -6.1% |
| 2011 Q1 | 1.07 Billion USD | -1.39% |
| 2010 Q1 | 787.15 Million USD | 6.2% |
| 2010 FY | 1.08 Billion USD | 46.98% |
| 2010 Q4 | 1.08 Billion USD | 15.6% |
| 2010 Q3 | 942.43 Million USD | 19.2% |
| 2010 Q2 | 790.64 Million USD | 0.44% |
| 2009 Q4 | 741.2 Million USD | -0.13% |
| 2009 FY | 741.2 Million USD | 10.62% |
| 2009 Q1 | 681.42 Million USD | 1.7% |
| 2009 Q2 | 742.34 Million USD | 8.94% |
| 2009 Q3 | 742.19 Million USD | -0.02% |
| 2008 Q1 | 930.87 Million USD | -0.57% |
| 2008 FY | 670.03 Million USD | -28.43% |
| 2008 Q2 | 851.22 Million USD | -8.56% |
| 2008 Q3 | 825.89 Million USD | -2.98% |
| 2008 Q4 | 670.03 Million USD | -18.87% |
| 2007 Q1 | 601.43 Million USD | 2.79% |
| 2007 FY | 936.25 Million USD | 60.02% |
| 2007 Q3 | 573.09 Million USD | -4.14% |
| 2007 Q2 | 597.85 Million USD | -0.59% |
| 2007 Q4 | 936.25 Million USD | 63.37% |
| 2006 Q1 | 402.08 Million USD | -5.06% |
| 2006 Q3 | 355.18 Million USD | -6.12% |
| 2006 FY | 585.09 Million USD | 38.16% |
| 2006 Q4 | 585.09 Million USD | 64.73% |
| 2006 Q2 | 378.33 Million USD | -5.91% |
| 2005 Q4 | 423.5 Million USD | 1.01% |
| 2005 Q3 | 419.27 Million USD | -6.19% |
| 2005 FY | 423.5 Million USD | -10.49% |
| 2005 Q2 | 446.94 Million USD | -4.96% |
| 2005 Q1 | 470.29 Million USD | -0.6% |
| 2004 Q3 | 472.68 Million USD | -3.17% |
| 2004 FY | 473.1 Million USD | -1.34% |
| 2004 Q4 | 473.1 Million USD | 0.09% |
| 2004 Q1 | 506.17 Million USD | 5.55% |
| 2004 Q2 | 488.17 Million USD | -3.56% |
| 2003 Q3 | 500.5 Million USD | 26.53% |
| 2003 Q2 | 395.54 Million USD | -8.11% |
| 2003 Q4 | 479.55 Million USD | -4.19% |
| 2003 FY | 479.55 Million USD | 22.47% |
| 2003 Q1 | 430.44 Million USD | 9.93% |
| 2002 Q1 | 471.86 Million USD | -4.75% |
| 2002 Q3 | 418.59 Million USD | -4.96% |
| 2002 Q2 | 440.45 Million USD | -6.66% |
| 2002 FY | 391.57 Million USD | -20.96% |
| 2002 Q4 | 391.57 Million USD | -6.45% |
| 2001 Q1 | 349.18 Million USD | 67.66% |
| 2001 Q4 | 495.39 Million USD | 55.49% |
| 2001 Q3 | 318.61 Million USD | -5.26% |
| 2001 Q2 | 336.29 Million USD | -3.69% |
| 2001 FY | 495.39 Million USD | 137.86% |
| 2000 FY | 208.27 Million USD | 52.02% |
| 2000 Q4 | 208.27 Million USD | -3.72% |
| 2000 Q3 | 216.31 Million USD | 7.03% |
| 2000 Q2 | 202.11 Million USD | 53.08% |
| 2000 Q1 | 132.03 Million USD | -3.62% |
| 1999 Q2 | 139.8 Million USD | -6.36% |
| 1999 FY | 137 Million USD | -12.68% |
| 1999 Q4 | 137 Million USD | 1.93% |
| 1999 Q3 | 134.4 Million USD | -3.86% |
| 1999 Q1 | 149.3 Million USD | -4.84% |
| 1998 Q4 | 156.9 Million USD | -3.39% |
| 1998 Q1 | 161.4 Million USD | -4.16% |
| 1998 Q2 | 165.1 Million USD | 2.29% |
| 1998 Q3 | 162.4 Million USD | -1.64% |
| 1998 FY | 156.9 Million USD | -6.83% |
| 1997 Q2 | 170 Million USD | 31.68% |
| 1997 Q3 | 164.7 Million USD | -3.12% |
| 1997 Q4 | 168.4 Million USD | 2.25% |
| 1997 Q1 | 129.1 Million USD | -6.18% |
| 1997 FY | 168.4 Million USD | 22.38% |
| 1996 Q2 | 139.3 Million USD | 61.6% |
| 1996 Q1 | 86.2 Million USD | -8.1% |
| 1996 FY | 137.6 Million USD | 46.7% |
| 1996 Q3 | 130.6 Million USD | -6.25% |
| 1996 Q4 | 137.6 Million USD | 5.36% |
| 1995 FY | 93.8 Million USD | -0.42% |
| 1995 Q1 | 86.1 Million USD | -8.6% |
| 1995 Q3 | 74.2 Million USD | -11.03% |
| 1995 Q2 | 83.4 Million USD | -3.14% |
| 1995 Q4 | 93.8 Million USD | 26.42% |
| 1994 FY | 94.2 Million USD | -19.9% |
| 1994 Q4 | 94.2 Million USD | -3.29% |
| 1994 Q2 | 105.7 Million USD | -0.28% |
| 1994 Q1 | 106 Million USD | -9.86% |
| 1994 Q3 | 97.4 Million USD | -7.85% |
| 1993 Q2 | 82.4 Million USD | -9.05% |
| 1993 Q4 | 117.6 Million USD | -6.59% |
| 1993 FY | 117.6 Million USD | 20.12% |
| 1993 Q3 | 125.9 Million USD | 52.79% |
| 1993 Q1 | 90.6 Million USD | -7.46% |
| 1992 Q2 | 108.7 Million USD | -3.12% |
| 1992 FY | 97.9 Million USD | -14.12% |
| 1992 Q4 | 97.9 Million USD | -6.23% |
| 1992 Q1 | 112.2 Million USD | -1.58% |
| 1992 Q3 | 104.4 Million USD | -3.96% |
| 1991 Q3 | 114 Million USD | -1.04% |
| 1991 Q2 | 115.2 Million USD | 0.0% |
| 1991 FY | 114 Million USD | 348.82% |
| 1991 Q4 | 114 Million USD | 0.0% |
| 1990 Q4 | 25.4 Million USD | 0.0% |
| 1990 FY | 25.4 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | -2122.991% |
| Alkermes plc | 2.13 Billion USD | -1448.537% |
| Agenus Inc. | 313.91 Million USD | -10438.015% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | -763.74% |
| Aptorum Group Limited | 20.64 Million USD | -160171.58% |
| Ardelyx, Inc. | 297.57 Million USD | -11016.443% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | -4221.091% |
| Bicycle Therapeutics plc | 595.34 Million USD | -5456.485% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -44783.721% |
| ChromaDex Corporation | 54.96 Million USD | -60085.212% |
| Chimerix, Inc. | 212.77 Million USD | -15447.106% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -116905.306% |
| Caribou Biosciences, Inc. | 440.96 Million USD | -7401.723% |
| CRISPR Therapeutics AG | 2.22 Billion USD | -1383.702% |
| Precision BioSciences, Inc. | 159.78 Million USD | -20603.463% |
| Dyadic International, Inc. | 8.21 Million USD | -402372.931% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -104122.432% |
| Fortress Biotech, Inc. | 167.52 Million USD | -19646.308% |
| Lantern Pharma Inc. | 43.64 Million USD | -75689.248% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -20403.79% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -227934.776% |
| Incyte Corporation | 6.78 Billion USD | -387.757% |
| IO Biotech, Inc. | 150.71 Million USD | -21848.407% |
| Jaguar Health, Inc. | 50.76 Million USD | -65065.967% |
| Novavax, Inc. | 1.85 Billion USD | -1682.97% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -8596.002% |
| Opthea Limited | 188.79 Million USD | -17422.108% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | -3870.907% |
| ContextLogic Inc. | 423 Million USD | -7720.378% |
| MiMedx Group, Inc. | 239.04 Million USD | -13738.367% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -18941.594% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -639786.137% |
| NextCure, Inc. | 129.41 Million USD | -25460.741% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -61218.677% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -89965.616% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -102312.309% |
| Vaxcyte, Inc. | 1.4 Billion USD | -2249.585% |
| PDS Biotechnology Corporation | 59.39 Million USD | -55599.874% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | -5064.367% |
| Pharming Group N.V. | 462.85 Million USD | -7047.005% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -85422.751% |
| Avidity Biosciences, Inc. | 628.55 Million USD | -5162.897% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -174708.54% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -174708.54% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -19909.799% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -72945.686% |
| Acelyrin, Inc. | 742.69 Million USD | -4354.106% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -502140.712% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -516535.952% |
| Summit Therapeutics Inc. | 202.94 Million USD | -16199.76% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -44378.178% |
| Senti Biosciences, Inc. | 119.48 Million USD | -27585.883% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -14387.129% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -19570.223% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -400241.28% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -692857.848% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | -6950.461% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -26652.444% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -11931.395% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | -6896.066% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -327264.671% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -15321.573% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -2921768.748% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | -7893.437% |
| Immix Biopharma, Inc. | 19.92 Million USD | -165922.255% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -8839.991% |
| MEI Pharma, Inc. | 41.37 Million USD | -79852.145% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -101980.479% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -9606.688% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -28119.407% |
| Fortress Biotech, Inc. | 167.52 Million USD | -19646.308% |
| Precigen, Inc. | 151.04 Million USD | -21801.18% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -97143.224% |
| AlloVir, Inc. | 190.79 Million USD | -17237.995% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -8687.385% |
| Fate Therapeutics, Inc. | 506.21 Million USD | -6434.786% |
| ImmuCell Corporation | 43.8 Million USD | -75411.603% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | -4994.623% |
| Onconetix, Inc. | 88.82 Million USD | -37143.482% |
| PureTech Health plc | 693.97 Million USD | -4666.785% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -33764.155% |
| Elevation Oncology, Inc. | 89.09 Million USD | -37030.799% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -533279.555% |
| Seer, Inc. | 436.26 Million USD | -7482.524% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -40440.951% |
| Innoviva, Inc. | 1.24 Billion USD | -2560.234% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -24880.706% |
| ESSA Pharma Inc. | 149.12 Million USD | -22083.294% |
| GlycoMimetics, Inc. | 45.31 Million USD | -72898.176% |
| GT Biopharma, Inc. | 14.1 Million USD | -234361.691% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -10644.057% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -13586.301% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | -6909.898% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -65150.804% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -34643.73% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -5237523.261% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | -5741.039% |
| Aptose Biosciences Inc. | 12.92 Million USD | -255888.295% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -149487.479% |
| Soligenix, Inc. | 9.79 Million USD | -337545.19% |
| Century Therapeutics, Inc. | 360.69 Million USD | -9071.341% |
| Kura Oncology, Inc. | 448.93 Million USD | -7268.595% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -12055.18% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -191170.309% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -29725.809% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -16024.806% |
| Autolus Therapeutics plc | 375.38 Million USD | -8712.433% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -13046.052% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -9213.539% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -67229.236% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | -4903.554% |
| GRI Bio, Inc. | 2.95 Million USD | -1118986.604% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -311823.574% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -19300.17% |
| IGM Biosciences, Inc. | 423.41 Million USD | -7712.787% |
| INmune Bio, Inc. | 57 Million USD | -57934.42% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -14767.105% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -39308.752% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -126562.25% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -480493.678% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -43874.424% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -22364.111% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -19887.553% |
| Coherus BioSciences, Inc. | 629.6 Million USD | -5154.128% |
| Verastem, Inc. | 149.71 Million USD | -21995.005% |
| Abeona Therapeutics Inc. | 64 Million USD | -51586.197% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | -6359.034% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -21317.093% |
| Histogen Inc. | 19.07 Million USD | -173339.941% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -145948.326% |
| Surrozen, Inc. | 46.08 Million USD | -71688.628% |
| Organovo Holdings, Inc. | 6.34 Million USD | -520930.083% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -767667.87% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -22868.089% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -280193.171% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -43849.886% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -388199.44% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -9013.781% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -182720.129% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | -7603.783% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -262197.292% |
| Apollomics, Inc. | 55.38 Million USD | -59625.567% |
| Amarin Corporation plc | 831.68 Million USD | -3877.496% |
| Mesoblast Limited | 669.15 Million USD | -4843.593% |
| Turnstone Biologics Corp. | 112.81 Million USD | -29222.519% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | -5645.494% |
| Synaptogenix, Inc. | 31.11 Million USD | -106220.48% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -271405.253% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | -5935.85% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -563229.866% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -450267.378% |
| Exelixis, Inc. | 2.94 Billion USD | -1024.276% |
| Better Therapeutics, Inc. | 22.94 Million USD | -144084.283% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -8974.53% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | -4094.11% |
| NLS Pharmaceutics AG | 1.84 Million USD | -1791271.469% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -414509.819% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -225011.943% |
| Gritstone bio, Inc. | 177.76 Million USD | -18508.531% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -34582.533% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -185095.947% |
| Avid Bioservices, Inc. | 336.55 Million USD | -9729.004% |
| Insmed Incorporated | 1.32 Billion USD | -2387.538% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -343470.988% |
| MediWound Ltd. | 66.45 Million USD | -49675.35% |
| OmniAb, Inc. | 401.98 Million USD | -8129.213% |
| Alector, Inc. | 621.82 Million USD | -5219.84% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -9124.819% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -615002.269% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -58250.737% |
| Zai Lab Limited | 1.03 Billion USD | -3092.161% |
| Revance Therapeutics, Inc. | 478.45 Million USD | -6813.977% |
| Aura Biosciences, Inc. | 255.07 Million USD | -12868.813% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | -4310.523% |
| Immunic, Inc. | 54.29 Million USD | -60822.301% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -12325.702% |
| Veracyte, Inc. | 1.13 Billion USD | -2807.329% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -279700.473% |
| FibroGen, Inc. | 423.52 Million USD | -7710.61% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -941551.011% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -698294.736% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -609170.357% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | -190.346% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -375597.899% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | -6292.877% |
| TG Therapeutics, Inc. | 329.58 Million USD | -9936.864% |
| Galecto, Inc. | 38.22 Million USD | -86436.218% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -115258.488% |
| Fortrea Holdings Inc. | 4.35 Billion USD | -659.208% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -13952.522% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -133062.386% |
| XBiotech Inc. | 227.24 Million USD | -14457.192% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -34582.533% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -23097.896% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -11469.902% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -25770.383% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -8559.761% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | -2118.639% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -8966.993% |
| Vaxxinity, Inc. | 44.35 Million USD | -74483.906% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | -6298.986% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -177661.361% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -10744.189% |
| NexImmune, Inc. | 8.59 Million USD | -384824.323% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -308622.477% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -193042.085% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -149238.65% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -8433025.566% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -18985.208% |
| Ainos, Inc. | 31.84 Million USD | -103789.214% |
| Pluri Inc. | 39.52 Million USD | -83590.136% |
| Prothena Corporation plc | 696.38 Million USD | -4650.295% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -11604.999% |
| Celularity Inc. | 143.88 Million USD | -22890.083% |
| Rallybio Corporation | 115.62 Million USD | -28511.14% |
| Cue Biopharma, Inc. | 61.53 Million USD | -53662.717% |
| MeiraGTx Holdings plc | 458.16 Million USD | -7120.103% |
| Omeros Corporation | 378.26 Million USD | -8645.152% |
| Humacyte, Inc. | 128.22 Million USD | -25698.96% |
| Immunocore Holdings plc | 597 Million USD | -5441.063% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -105726.162% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -48171.122% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -3052.747% |
| CalciMedica, Inc. | 12.18 Million USD | -271382.971% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -12941.672% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -19255.56% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -10535.523% |
| Sana Biotechnology, Inc. | 565.29 Million USD | -5751.806% |
| Pulmatrix, Inc. | 33.95 Million USD | -97315.042% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -121760.311% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -23384.786% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -2442.72% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -25309.361% |
| Cytokinetics, Incorporated | 824.31 Million USD | -3913.048% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -156507.489% |
| Nutriband Inc. | 7.51 Million USD | -439962.822% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -41798.067% |
| Vor Biopharma Inc. | 209.82 Million USD | -15665.389% |
| Roivant Sciences Ltd. | 7.22 Billion USD | -358.017% |
| Evogene Ltd. | 51.1 Million USD | -64634.937% |
| ProKidney Corp. | 420.55 Million USD | -7765.9% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -60228.999% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -347370.946% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | -5954.431% |
| CorMedix Inc. | 82.05 Million USD | -40212.232% |
| BioLineRx Ltd. | 63.92 Million USD | -51648.455% |
| Tango Therapeutics, Inc. | 402.56 Million USD | -8117.315% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -117205.674% |
| Atai Life Sciences N.V. | 293.47 Million USD | -11171.782% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -20178.497% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -25861.952% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | -5785.874% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -34102.38% |
| MediciNova, Inc. | 66.26 Million USD | -49817.325% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -37513.362% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -741215.424% |
| GeoVax Labs, Inc. | 9.28 Million USD | -356244.066% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -5523.627% |
| Biomea Fusion, Inc. | 199.92 Million USD | -16446.139% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | -1638.153% |
| Mereo BioPharma Group plc | 66.49 Million USD | -49645.41% |
| Cullinan Oncology, Inc. | 485.09 Million USD | -6719.31% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | -5297.5% |
| Absci Corporation | 234.48 Million USD | -14007.898% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -452124.197% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -9632.591% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -19938.647% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | -6185.164% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -11812.508% |
| Allakos Inc. | 243.61 Million USD | -13479.163% |
| Imunon, Inc. | 21.91 Million USD | -150826.617% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -12737.008% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -5222.493% |
| BioAtla, Inc. | 119.65 Million USD | -27545.623% |
| NLS Pharmaceutics AG | 1.84 Million USD | -1791271.469% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -1027235.404% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | -5045.97% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -34381.889% |
| XOMA Corporation | 234.3 Million USD | -14018.676% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -14852.517% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -26186.672% |
| aTyr Pharma, Inc. | 122.06 Million USD | -27000.035% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -21394.188% |
| Akero Therapeutics, Inc. | 580.27 Million USD | -5600.819% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | -6645.225% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -29845.234% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -218142.264% |
| Akari Therapeutics, Plc | 4.35 Million USD | -759491.274% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -194063.018% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | -1808.543% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -1072544.299% |
| UroGen Pharma Ltd. | 178.31 Million USD | -18451.968% |
| Sutro Biopharma, Inc. | 470.73 Million USD | -6927.336% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -5952627.567% |
| Orgenesis Inc. | 14.55 Million USD | -227224.079% |
| Entera Bio Ltd. | 11.76 Million USD | -281074.671% |
| GH Research PLC | 226.3 Million USD | -14517.852% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -60382.32% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -30690.61% |
| Xencor, Inc. | 952.69 Million USD | -3372.287% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -424889.379% |
| Replimune Group, Inc. | 487.72 Million USD | -6682.593% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -409760.429% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | -5001.505% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -1072544.299% |
| Portage Biotech Inc. | 7.77 Million USD | -425150.032% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -741215.424% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -11844.682% |
| OncoCyte Corporation | 74.89 Million USD | -44070.539% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -1626863.361% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -571564.78% |
| Purple Biotech Ltd. | 44.3 Million USD | -74569.767% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -96835.474% |
| scPharmaceuticals Inc. | 94.47 Million USD | -34913.283% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -183221.014% |
| HilleVax, Inc. | 344.43 Million USD | -9504.22% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -1041468.01% |
| Tharimmune, Inc. | 10.94 Million USD | -302101.83% |
| Genprex, Inc. | 10.67 Million USD | -309912.79% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | -6566.774% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -34268.325% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -1363469.662% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -794058.41% |
| OKYO Pharma Limited | 1.54 Million USD | -2146203.294% |
| Savara Inc. | 177.56 Million USD | -18530.015% |
| Curis, Inc. | 77.28 Million USD | -42704.534% |
| Daré Bioscience, Inc. | 21.28 Million USD | -155335.889% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -51629.193% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -409004.625% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -170671.772% |
| BeiGene, Ltd. | 5.8 Billion USD | -469.83% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -271739.921% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | -1483.852% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -9141.544% |
| Erasca, Inc. | 395.29 Million USD | -8268.442% |
| bluebird bio, Inc. | 619.16 Million USD | -5242.746% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -765048.661% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | -383.515% |
| DBV Technologies S.A. | 182.98 Million USD | -17977.995% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -765048.661% |
| Moderna, Inc. | 18.42 Billion USD | -79.53% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -181489.724% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -285418.73% |
| Molecular Templates, Inc. | 35.38 Million USD | -93391.79% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -23825.216% |
| Travere Therapeutics, Inc. | 788.91 Million USD | -4093.137% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -10790.422% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -31724.409% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | -7004.442% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -10454.019% |
| MacroGenics, Inc. | 306.82 Million USD | -10681.631% |
| RenovoRx, Inc. | 1.46 Million USD | -2256393.861% |
| Adicet Bio, Inc. | 207.29 Million USD | -15858.031% |
| Prime Medicine, Inc. | 193.85 Million USD | -16964.756% |
| Aditxt, Inc. | 44.57 Million USD | -74106.912% |
| Adagene Inc. | 115.72 Million USD | -28484.232% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -742576.164% |
| Quantum-Si incorporated | 298.25 Million USD | -10991.433% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | -2123.954% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -429004.582% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -9317.019% |
| SciSparc Ltd. | 11.18 Million USD | -295734.377% |
| Vericel Corporation | 353.65 Million USD | -9253.752% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -270769.23% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -58036.809% |
| Generation Bio Co. | 374.75 Million USD | -8727.083% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -12889.641% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -20761.97% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -9590.566% |
| Invivyd, Inc. | 229.18 Million USD | -14334.094% |
| Relay Therapeutics, Inc. | 843.98 Million USD | -3819.548% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -271733.197% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -18037.069% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -161867.293% |
| 2seventy bio, Inc. | 565.42 Million USD | -5750.491% |
| ADMA Biologics, Inc. | 329.18 Million USD | -9949.213% |
| Clene Inc. | 52.34 Million USD | -63101.314% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -56221.749% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -25367.073% |
| GeoVax Labs, Inc. | 9.28 Million USD | -356244.066% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | -4960.464% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -31827.259% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -25270.975% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -33810.31% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -46493.8% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -13538.339% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | -1587.688% |
| Evaxion Biotech A/S | 12.88 Million USD | -256562.099% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -13023.939% |
| Verve Therapeutics, Inc. | 752.68 Million USD | -4294.942% |
| Trevena, Inc. | 40.6 Million USD | -81368.292% |
| Surrozen, Inc. | 46.08 Million USD | -71688.628% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -14546.524% |
| Cingulate Inc. | 3.49 Million USD | -947366.888% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -198830.784% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -50258.045% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -283008.738% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -12219.592% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | -4316.842% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -26176.65% |
| Clearmind Medicine Inc. | 4.32 Million USD | -764868.184% |
| Kronos Bio, Inc. | 213.27 Million USD | -15410.294% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -20603.074% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -386323.397% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -8877.231% |
| Statera Biopharma, Inc. | 21.16 Million USD | -156162.127% |
| ImmunityBio, Inc. | 504.45 Million USD | -6457.651% |
| Korro Bio, Inc. | 221.66 Million USD | -14823.645% |
| Kineta, Inc. | 10.28 Million USD | -321660.529% |
| BioVie Inc. | 25.2 Million USD | -131127.179% |
| Codexis, Inc. | 136.56 Million USD | -24123.753% |
| Celularity Inc. | 143.88 Million USD | -22890.083% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | -5106.586% |
| Celcuity Inc. | 191.21 Million USD | -17199.605% |
| Virax Biolabs Group Limited | 5.48 Million USD | -603116.393% |
| Cibus, Inc. | 544.41 Million USD | -5976.328% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -26176.232% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -160921.223% |
| IN8bio, Inc. | 33.7 Million USD | -98034.623% |
| Kodiak Sciences Inc. | 479.37 Million USD | -6800.737% |
| Annexon, Inc. | 297.67 Million USD | -11012.895% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -19020.398% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -23963.753% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -157477.288% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | -1006.335% |
| Eyenovia, Inc. | 28.77 Million USD | -114844.126% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -14249.754% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -457820.819% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -54195.703% |
| Arcellx, Inc. | 825.13 Million USD | -3909.08% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -40421.087% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | -7055.957% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -107477.886% |
| Moolec Science SA | 24.05 Million USD | -137440.237% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -10566.731% |
| Geron Corporation | 394.07 Million USD | -8294.371% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -32424.039% |
| Royalty Pharma plc | 16.38 Billion USD | -101.932% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | -5459.997% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -472824.588% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -274942.246% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -14533.372% |
| Humacyte, Inc. | 128.22 Million USD | -25698.96% |
| Structure Therapeutics Inc. | 482.01 Million USD | -6762.869% |
| 89bio, Inc. | 596.26 Million USD | -5447.865% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -13019.15% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -1788018.919% |
| Genelux Corporation | 27.89 Million USD | -118496.781% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -36901.219% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -14318.491% |
| Notable Labs, Ltd. | 19.54 Million USD | -169186.116% |
| Liquidia Corporation | 120.43 Million USD | -27368.177% |
| Mustang Bio, Inc. | 17.74 Million USD | -186351.358% |
| Immunovant, Inc. | 666.71 Million USD | -4861.693% |
| Quantum-Si incorporated | 298.25 Million USD | -10991.433% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -22808.567% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -60978.656% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -18744.178% |
| Acasti Pharma Inc. | 73.3 Million USD | -45029.877% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -726573.068% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -126562.25% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | -3328.718% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -637293.5% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -145109.604% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -64005.188% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -18207.608% |
| PepGen Inc. | 143.05 Million USD | -23024.598% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -86458.861% |
| United Therapeutics Corporation | 7.16 Billion USD | -361.563% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -172327.417% |
| Solid Biosciences Inc. | 164.93 Million USD | -19956.021% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -563229.866% |
| Immuneering Corporation | 102.58 Million USD | -32146.77% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -767667.87% |
| Silo Pharma, Inc. | 7.74 Million USD | -426953.936% |
| Belite Bio, Inc | 94.64 Million USD | -34852.981% |
| XOMA Corporation | 234.3 Million USD | -14018.676% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -14086.064% |
| Bionomics Limited | 27.64 Million USD | -119542.984% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | -8141.124% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -30704.373% |
| uniQure N.V. | 831.68 Million USD | -3877.472% |
| Cassava Sciences, Inc. | 151.66 Million USD | -21711.648% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -742576.164% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -11978.135% |
| Forte Biosciences, Inc. | 38.98 Million USD | -84764.546% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -812059.935% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -89716.187% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -457820.819% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -941551.011% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -279742.653% |
| Altimmune, Inc. | 210.64 Million USD | -15604.615% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -4152.61% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -30704.373% |
| Compugen Ltd. | 121.33 Million USD | -27163.751% |
| Peak Bio, Inc. | 2.59 Million USD | -1273972.134% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -19096.179% |
| Benitec Biopharma Inc. | 52.21 Million USD | -63259.893% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -9576.563% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -95031.855% |
| Zura Bio Limited | 100.84 Million USD | -32703.665% |
| PolyPid Ltd. | 15.37 Million USD | -215097.762% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -27631.838% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -95031.855% |
| Instil Bio, Inc. | 325.63 Million USD | -10058.831% |
| argenx SE | 4.54 Billion USD | -628.244% |
| Immunome, Inc. | 148.54 Million USD | -22170.23% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -20986.98% |
| Verona Pharma plc | 308.12 Million USD | -10636.002% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -37941.146% |
| Shattuck Labs, Inc. | 159.56 Million USD | -20631.619% |
| CervoMed Inc. | 9.97 Million USD | -331613.516% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -17453.275% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -290382.965% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -18338.839% |
| Moolec Science SA | 24.05 Million USD | -137440.237% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -540648.805% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -19027.648% |
| AnaptysBio, Inc. | 452.38 Million USD | -7212.335% |
| Design Therapeutics, Inc. | 289.64 Million USD | -11321.025% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -45324.236% |
| NeurAxis, Inc. | 509.49 Thousand USD | -6492604.584% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -610461.093% |
| Lumos Pharma, Inc. | 40.63 Million USD | -81302.136% |
| Achilles Therapeutics plc | 161.45 Million USD | -20388.678% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -37941.146% |
| 180 Life Sciences Corp. | 5.25 Million USD | -628863.798% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -46870.374% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -386323.397% |
| Nutriband Inc. | 7.51 Million USD | -439962.822% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -12888.621% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -16498.11% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -43305.5% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -57017.55% |
| MoonLake Immunotherapeutics | 526.54 Million USD | -6182.56% |
| Palisade Bio, Inc. | 14.05 Million USD | -235312.753% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -15630.379% |
| Beam Therapeutics Inc. | 1.45 Billion USD | -2166.211% |
| Neurogene Inc. | 222.57 Million USD | -14762.629% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | -5015.856% |
| AEON Biopharma, Inc. | 6.84 Million USD | -483175.383% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | -7201.892% |
| Sesen Bio, Inc. | 189.17 Million USD | -17386.652% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -12067.788% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -241152.287% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -4139.144% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -12289.866% |
| Athira Pharma, Inc. | 160.24 Million USD | -20543.515% |
| Vaccinex, Inc. | 3.63 Million USD | -910949.298% |
| HCW Biologics Inc. | 28.51 Million USD | -115915.271% |
| XOMA Corporation | 234.3 Million USD | -14018.676% |
| Nektar Therapeutics | 398.03 Million USD | -8210.919% |
| Arvinas, Inc. | 1.3 Billion USD | -2435.658% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -194063.018% |
| Merus N.V. | 458.49 Million USD | -7114.969% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -16086.743% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -18257.084% |
| Rezolute, Inc. | 132.73 Million USD | -24821.612% |
| Clene Inc. | 52.34 Million USD | -63101.314% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -221559.545% |
| BeyondSpring Inc. | 24.8 Million USD | -133244.889% |
| Synlogic, Inc. | 75.55 Million USD | -43685.837% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -278775.4% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -353169.97% |
| Peak Bio, Inc. | 2.59 Million USD | -1273972.134% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -18821.027% |
| Krystal Biotech, Inc. | 818.35 Million USD | -3942.28% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -13658.308% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | -4457.832% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -924657.923% |
| MannKind Corporation | 475.19 Million USD | -6861.351% |
| Ikena Oncology, Inc. | 192.09 Million USD | -17121.019% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -247247.091% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -28285.519% |
| Gossamer Bio, Inc. | 311.91 Million USD | -10505.484% |
| CohBar, Inc. | 16.36 Million USD | -202031.694% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -93976.728% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -452124.197% |
| Legend Biotech Corporation | 1.84 Billion USD | -1689.464% |
| Mural Oncology plc | 301.74 Million USD | -10862.965% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -105875.332% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -582256.364% |
| Disc Medicine, Inc. | 367.99 Million USD | -8889.282% |
| Champions Oncology, Inc. | 26.13 Million USD | -126488.857% |
| REGENXBIO Inc. | 573.97 Million USD | -5663.402% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -1221434.775% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -21326.943% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -273842.949% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -9628.469% |
| Vaxart, Inc. | 91.83 Million USD | -35923.304% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -55122.13% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -22202.224% |
| Cellectis S.A. | 334.27 Million USD | -9796.252% |
| Longeveron Inc. | 12.17 Million USD | -271539.021% |
| Repare Therapeutics Inc. | 253.9 Million USD | -12928.779% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | -913.308% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -16370.348% |
| Revolution Medicines, Inc. | 2.08 Billion USD | -1483.852% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -2035604.615% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -11811.736% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -20182.407% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -23742.617% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -129514.45% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | -45.534% |
| Denali Therapeutics Inc. | 1.15 Billion USD | -2766.775% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -270769.23% |
| Veru Inc. | 50.59 Million USD | -65281.155% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -72519.147% |
| Cingulate Inc. | 3.49 Million USD | -947366.888% |
| Passage Bio, Inc. | 150.54 Million USD | -21873.629% |
| Context Therapeutics Inc. | 16.06 Million USD | -205843.757% |
| Exicure, Inc. | 11.58 Million USD | -285566.667% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -8696.803% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -20365.102% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -189232.647% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -9841.607% |
| Nuvalent, Inc. | 732.38 Million USD | -4416.784% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -221259.911% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -36838.83% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -233006.899% |
| OmniAb, Inc. | 401.98 Million USD | -8129.213% |
| Anew Medical, Inc. | 19.45 Million USD | -169926.11% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -123672.78% |
| Lipocine Inc. | 23 Million USD | -143720.253% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -23561.333% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -10725.913% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -39308.752% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -27117.542% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -416789.729% |
| Sage Therapeutics, Inc. | 882.27 Million USD | -3649.412% |
| Ocugen, Inc. | 64.54 Million USD | -51149.787% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -26461.695% |
| Q32 Bio Inc. | 306.11 Million USD | -10706.32% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -786026.426% |
| Alumis Inc. Common Stock | 89.61 Million USD | -36814.922% |
| Equillium, Inc. | 50.53 Million USD | -65366.456% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -43892.553% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -80048.717% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -1944818.226% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -126445.274% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -51234.089% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -887455.596% |
| Dominari Holdings Inc. | 57.55 Million USD | -57372.81% |
| Edesa Biotech, Inc. | 8.89 Million USD | -371987.446% |
| vTv Therapeutics Inc. | 11.01 Million USD | -300137.793% |
| Bio-Techne Corporation | 2.81 Billion USD | -1075.896% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -3429.993% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | -3976.688% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -11813.709% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -79225.212% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | -4855.182% |
| Nkarta, Inc. | 378.88 Million USD | -8630.934% |
| BioCardia, Inc. | 2.98 Million USD | -1107372.38% |
| Iterum Therapeutics plc | 26.25 Million USD | -125876.618% |